Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04940052 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT04940052 · ClinicalTrials.gov record · last posted 2026-06-26

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer

StatusActive, Not Recruiting
PhasePhase 3
Started2021-11-15
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The purpose of this study is to assess the efficacy and safety of dabrafenib in combination with trametinib for treating adult patients with locally advanced or metastatic Differentiated Thyroid Cancer (DTC) harboring the BRAFV600E mutation, who are refractory to radioactive iodine (RAI) therapy and have experienced disease progression following one or two prior VEGFR-targeted treatments.

Amendment record 42 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 42 times since 2021-06-22; most recent amendment 2026-06-10. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2024-06-12
Status change Recruiting→Active, Not Recruitingv21
2021-11-17
Status change Not Yet Recruiting→Recruitingv3
Trial Details
NCT Number NCT04940052
Lead Sponsor Novartis Pharmaceuticals
Conditions Differentiated Thyroid Cancer (DTC)
Enrollment 153 participants
Start Date 2021-11-15
Primary Completion 2025-01-22 (estimated)
Study Completion 2027-05-25 (estimated)
Updated on ClinicalTrials.gov 2026-06-26